Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1700034

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make a comparative assessment of the adequacy of the reasons the (a) National Institute for Health and Care Excellence has been unable and (b) Scottish Medicines Consortium has been able to recommend Enhertu for use on the NHS.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	20959
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes authoritative, evidence-based recommendations for the National Health Service in England on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. Decisions on the availability of medicines in Scotland are a matter for the devolved administration.</p><p>The NICE published guidance in 2021 and 2023 recommending Enhertu, also known as trastuzumab deruxtecan, for the treatment of NHS patients with HER2-positive breast cancer through the Cancer Drugs Fund, and it is now available to eligible NHS patients in England in line with the NICE’s recommendations.</p><p>The NICE is currently evaluating Enhertu for the treatment of metastatic HER2-low breast cancer, and has not yet published final guidance. Stakeholders have had an opportunity to appeal against the NICE’s draft recommendations, and the NICE will consider any appeals through the established process and publish final guidance in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 15:01:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas

1700068

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether NICE is taking steps to make Enhertu available to the National Health Service to treat incurable HER2-low secondary breast cancer.
	tabling member constituency	South Holland and The Deepings
	tabling member printed	Sir John Hayes
	uin	20865
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on whether Enhertu can be recommended for routine NHS funding, based on an assessment of the costs and benefits. The NICE was unfortunately unable to recommend Enhertu as a clinically and cost-effective use of NHS resources in its final draft guidance published on 5 March 2024. Stakeholders have had an opportunity to appeal against the NICE’s draft recommendations, and the NICE will consider any appeals through the established process, and will publish final guidance in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 15:03:45 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	350 label Biography information for Sir John Hayes

1696698

	registered interest
	date	18/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential impact of the decision by the National Institute for Health and Care Excellence to not recommend trastuzumab deruxtecan for HER2-low secondary breast cancer for use on NHS on the life expectancy of eligible women.
	tabling member constituency	North Warwickshire
	tabling member printed	Craig Tracey
	uin	19119
	answer	answer is ministerial correction date of answer 21/03/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) has not yet published final guidance on the use of trastuzumab deruxtecan (Enhertu) for the treatment of metastatic HER2-low breast cancer. The NICE published final draft guidance on 5 March 2024, that does not recommend it as a clinically and cost-effective use of National Health Service resources. Stakeholders had until 19 March 2024 to lodge an appeal against the NICE’s recommendations. The NICE currently expects to publish final guidance on 3 April 2024.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 21/03/2024 17:10:39 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4509 label Biography information for Craig Tracey

1695647

	registered interest
	date	13/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if her Department will take steps to encourage the England-wide roll-out of the drug Enhertu to aid the treatment of people with breast cancer.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	uin	18402
	answer	answer is ministerial correction date of answer 18/03/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance on whether new licensed medicines should be routinely funded by the National Health Service, based on an assessment of their costs and benefits.</p><p>The NICE published guidance in 2021 and 2023 recommending Enhertu (trastuzumab deruxtecan) for the treatment of NHS patients with HER2-positive breast cancer through the Cancer Drugs Fund, and it is now available to eligible NHS patients in line with the NICE’s recommendations.</p><p>The NICE is currently evaluating Enhertu for the treatment of metastatic HER2-low breast cancer, and published final draft guidance on 5 March 2024 that does not recommend it as a clinically and cost-effective use of NHS resources. Stakeholders have until 19 March 2024 to lodge an appeal against the NICE’s recommendations. The NICE currently expects to publish final guidance on 3 April 2024.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/03/2024 15:32:05 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1447 label Biography information for Andrew Rosindell

1673991

	registered interest
	date	29/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the National Institute for Health and Care Excellence on when it plans to conclude its appraisal of trastuzumab deruxtecan for treating HER2-low metastatic or unrespectable breast cancer after chemotherapy.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	4364
	answer	answer is ministerial correction date of answer 05/12/2023 answer text <p>We have had no such discussions. The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on trastuzumab deruxtecan for HER2-low metastatic or unresectable breast cancer after chemotherapy, and recently consulted on draft guidance that does not recommend it as a clinically and cost-effective use of NHS resources. NICE will carefully consider comments received in response to the consultation in developing its final guidance, which is currently expected to be published in January 2024.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 05/12/2023 16:09:54 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

1645697

	registered interest
	date	19/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the National Institute for Health and Care Excellence is taking steps to approve Enhertu for use in the treatment of cancers other than breast cancer.
	tabling member constituency	Meriden
	tabling member printed	Saqib Bhatti
	uin	190164
	answer	answer is ministerial correction date of answer 26/06/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently in the early stages of developing technology appraisal guidance on treatments for non-small-cell lung cancer, including Enhertu (trastuzumab deruxtecan) and held a scoping workshop focusing on this topic on 24 April 2023.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 26/06/2023 12:53:14 answering member 4527 label Biography information for Helen Whately
	tabling member	4818 label Biography information for Saqib Bhatti